Abstract：
Aim: This real-world study aimed to describe patient and clinical characteristics, treatment patterns and outcomes for patients with HR+/HER2- metastatic breast cancer receiving abemaciclib in France, Italy and Spain. Materials & methods: A multicenter chart review was conducted for adult females with HR+/HER2- advanced/metastatic breast cancer who received abemaciclib in routine care. Real-world progression-free survival (rwPFS) was estimated via Kaplan-Meier curves. Results: This study included 151, 173 and 175 patients from France, Italy and Spain, respectively. Abemaciclib was mostly prescribed as first-line therapy concomitantly with hormone therapy. Median rwPFS was >20 months and the 1-year rwPFS rate was >70%. Conclusion: Effectiveness was similar across the three countries and aligns with pivotal studies.
Abemaciclib use in the clinic in France, Italy & SpainThis study describes patients, the treatments they have received and the results of those treatments for patients with the most common type of advanced breast cancer. These patients were taking abemaciclib plus hormonal therapy in routine breast cancer care in France, Italy and Spain. The information used to conduct this study was taken from patients\' medical charts. In this real-world study, abemaciclib was mostly used as the initial treatment for advanced breast cancer. Abemaciclib effectiveness was similar across the three countries confirming findings from previous studies. Our study supports the use of abemaciclib for patients with HR+/HER2- advanced breast cancer.
Abemaciclib use in the clinic in France, Italy & SpainThis study describes patients, the treatments they have received and the results of those treatments for patients with the most common type of advanced breast cancer. These patients were taking abemaciclib plus hormonal therapy in routine breast cancer care in France, Italy and Spain. The information used to conduct this study was taken from patients\' medical charts. In this real-world study, abemaciclib was mostly used as the initial treatment for advanced breast cancer. Abemaciclib effectiveness was similar across the three countries confirming findings from previous studies. Our study supports the use of abemaciclib for patients with HR+/HER2- advanced breast cancer.
摘要：
目的：这项真实世界的研究旨在描述患者和临床特征，在法国接受abemaciclib治疗的HR+/HER2-转移性乳腺癌患者的治疗模式和结果，意大利和西班牙。材料与方法：对接受abemaciclib常规护理的HR+/HER2-晚期/转移性乳腺癌成年女性进行了多中心图表审查。通过Kaplan-Meier曲线估计真实世界无进展生存期(rwPFS)。结果：这项研究包括来自法国的151、173和175名患者，意大利和西班牙,分别。Abemaciclib主要是在激素治疗的同时作为一线治疗。rwPFS中位数>20个月，1年rwPFS率>70%。结论：三个国家的有效性相似，与关键研究一致。
在法国诊所使用Abemaciclib,意大利和西班牙这项研究描述了患者，他们接受的治疗以及对最常见的晚期乳腺癌患者的治疗结果。这些患者在法国的常规乳腺癌护理中服用abemaciclib加激素治疗，意大利和西班牙。用于进行这项研究的信息取自患者的医疗图表。在现实世界的研究中,abemaciclib主要用作晚期乳腺癌的初始治疗。三个国家的Abemaciclib有效性相似，证实了先前研究的结果。我们的研究支持对HR+/HER2-晚期乳腺癌患者使用abemaciclib。
在法国诊所使用Abemaciclib,意大利和西班牙这项研究描述了患者，他们接受的治疗以及对最常见的晚期乳腺癌患者的治疗结果。这些患者在法国的常规乳腺癌护理中服用abemaciclib加激素治疗，意大利和西班牙。用于进行这项研究的信息取自患者的医疗图表。在现实世界的研究中,abemaciclib主要用作晚期乳腺癌的初始治疗。三个国家的Abemaciclib有效性相似，证实了先前研究的结果。我们的研究支持对HR+/HER2-晚期乳腺癌患者使用abemaciclib。
